Lipocine (LPCN)

• Market cap: $16.1M
• 1 day: 1.36%
• 5 days: 2.05%
• 1 month: 0.34%
• 3 months: -5.7%
• 6 months: -7.17%
• Year to date: -38.68%
• 1 year: -26.96%
• 5 years: -86.82%
• 10 years: -98.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Employees: 16

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1% more capital invested

Capital invested by funds: $1.65M [Q1] → $1.67M (+$24.5K) [Q2]

0.2% more ownership

Funds ownership: 9.67% [Q1] → 9.88% (+0.2%) [Q2]

5% less funds holding

Funds holding: 19 [Q1] → 18 (-1) [Q2]

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8
• Avg. target: $8
• High target: $8

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen

$8

Buy Reiterated

20 Aug 2025